Hormonal Contraceptives Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Method (Pill, Intrauterine Device, Injectable, Vaginal Ring, Implant, Others), By Hormone (Combination Hormonal Contraceptives, Progestin Only), By Region and Competition, 2020-2030F

Market Overview

Global Hormonal Contraceptives Market was valued at USD 17.25 Billion in 2024 and is expected to reach USD 25.57 Billion by 2030 with a CAGR of 6.78% during the forecast period. The global market for Hormonal Contraceptives is experiencing significant growth, driven by the growing awareness regarding usage of oral contraceptive and its benefits for preventing the unintended pregnancy and population control significantly increased the demand for hormonal contraceptives across different parts of the globe. Additionally, ahavetion of hormonal contraceptives has significantly increased and increasing awareness among women of different age group for leading the safe life is further expected to increase the demand for different hormonal contraceptives procedures, thereby fuelling the market growth. For instance, in April 2021, the Food and Drug Administration approved a combination of drospirenone and estetrol tablet Nextstellis marketed by Mayne Pharma for preventing pregnancy, one of the first combination pills containing naturally occurring estrogen.

Key Market Drivers

Rising Government Initiatives to Promote Family Planning and Reproductive Health

One of the primary drivers of growth in the global hormonal contraceptives market is the significant investment by governments and international health organizations in reproductive health and family planning programs. Hormonal contraceptives—including oral pills, patches, injections, implants, and vaginal rings—form the cornerstone of modern contraception. Their widespread availability and integration into public health systems are largely supported by government policies that aim to reduce unintended pregnancies, maternal mortality, and child morbidity. The World Health Organization (WHO) states that around 257 million women globally who want to avoid pregnancy are not using safe or modern contraceptive methods. To address this unmet need, numerous governments have scaled up access to hormonal contraceptives through national programs. For instance, the U.S. federal Title X Family Planning Program supports clinics in offering affordable or free birth control to low-income individuals. According to the Office of Population Affairs (OPA), Title X clinics served 1.5 million individuals in 2022 alone, and over 99% of those clients received contraceptive services.

In developing countries, such as India, the Ministry of Health and Family Welfare operates the National Family Planning Program, which provides subsidized contraceptives through public health centers. As of 2023, the Indian government distributed over 20 million cycles of oral contraceptive pills under its Mission Parivar Vikas scheme. These expansive efforts ensure continuous market demand for hormonal contraceptives and stimulate innovation and supply chain efficiency. In effect, public health policies aimed at increasing contraceptive prevalence are driving hormonal contraceptive market growth across regions.

Growing Female Workforce Participation and Delayed Childbearing

Another significant factor driving the hormonal contraceptives market is the global shift toward delayed childbearing, influenced by the rise in female workforce participation and evolving societal norms. Women are increasingly prioritizing higher education, professional development, and financial stability before starting a family. Hormonal contraceptives offer the flexibility and reliability needed to delay pregnancy, making them integral to modern reproductive planning. Data from the U.S. Bureau of Labor Statistics (BLS) shows that in 2023, approximately 77% of women aged 25 to 54 were participating in the labor force, a figure that has been steadily increasing in both developed and developing economies. In parallel, the median age of first-time mothers in countries like the United States, Japan, and Germany has risen significantly over the past two decades. The U.S. Centers for Disease Control and Prevention (CDC) reported that the average age of first-time mothers in the U.S. rose to 27.3 years in 2022 from 24.9 years in 2000.

This shift supports the demand for long-acting reversible contraceptives (LARCs) such as implants and intrauterine devices (IUDs), as well as short-term options like oral pills and contraceptive patches. The increased demand for hormonal birth control stems from its effectiveness, convenience, and ability to align with women's personal and professional life plans. Thus, as more women delay childbearing in pursuit of career and educational goals, the reliance on hormonal contraceptive methods is expected to grow, driving long-term market expansion.

Download Free Sample Report

Key Market Challenges

Health Risks and Side Effects Associated with Hormonal Contraceptives

Despite their widespread use and effectiveness, hormonal contraceptives are associated with various health risks and side effects, which pose a significant challenge to market growth. Hormonal contraceptives function by altering a woman's hormone levels to prevent ovulation, and this hormonal interference can lead to adverse effects such as mood swings, weight gain, nausea, headaches, and menstrual irregularities. More serious risks include an increased likelihood of blood clots, cardiovascular complications, and, in rare cases, certain types of cancer. A study by the National Cancer Institute (NCI) reported a slight increase in the risk of breast and cervical cancer among long-term users of hormonal contraceptives, although they may reduce the risk of ovarian and endometrial cancers.

In 2019, the U.S. Food and Drug Administration (FDA) updated warnings on combined hormonal contraceptives (CHCs) about the risk of venous thromboembolism (VTE), especially for products containing drospirenone. Similarly, regulatory agencies in Europe, such as the European Medicines Agency (EMA), have recommended stronger warnings and educational efforts to ensure informed use. Concerns about side effects can lead to discontinuation or switching to non-hormonal methods, particularly in high-risk populations such as smokers over 35, obese individuals, and those with hypertension or a family history of thrombotic disorders. These health considerations reduce user confidence and affect market penetration, especially among new adopters. As awareness of potential adverse effects grows, particularly through social media and health advocacy platforms, it may hinder widespread adoption unless offset by education, personalized medical guidance, and the development of safer formulations.

Sociocultural and Religious Barriers to Contraceptive Use

Another substantial challenge facing the hormonal contraceptives market is the presence of sociocultural and religious barriers that influence attitudes toward birth control. In several regions, particularly in parts of the Middle East, Africa, and South Asia, contraceptive use remains taboo due to traditional beliefs, patriarchal social structures, and religious teachings that discourage artificial birth control. For instance, according to the United Nations Population Fund (UNFPA), countries such as Nigeria and Pakistan have some of the highest unmet needs for family planning, with modern contraceptive prevalence rates as low as 12-20% in some regions. In Afghanistan, where cultural restrictions on female autonomy remain deeply rooted, female access to reproductive healthcare, including hormonal contraception, has sharply declined since 2021 under Taliban rule, leading to increased rates of unplanned pregnancies.

Moreover, in Latin American countries with strong Catholic influence, such as Honduras and El Salvador, societal norms significantly restrict open discussions and policy development around contraception. The World Bank notes that restrictive legal frameworks and lack of sex education further exacerbate the issue in these regions. These barriers limit product uptake, hinder education campaigns, and discourage women from seeking reproductive care. To overcome this challenge, stakeholders must engage in culturally sensitive awareness campaigns, collaborate with local religious and community leaders, and ensure privacy and discretion in service delivery. The persistence of these sociocultural challenges undermines global efforts to ensure universal access to hormonal contraceptives and impedes equitable market growth across different regions.

Key Market Trends

Increasing Preference for Long-Acting Reversible Contraceptives (LARCs)

A prominent trend reshaping the hormonal contraceptives landscape is the growing preference for Long-Acting Reversible Contraceptives (LARCs) such as hormonal intrauterine devices (IUDs) and subdermal implants. These methods offer extended protection ranging from three to ten years, minimal maintenance, and high efficacy—qualities that are increasingly appealing to women globally, particularly those seeking convenience and long-term reproductive autonomy. According to the U.S. Centers for Disease Control and Prevention (CDC), LARCs have the lowest failure rates among contraceptive methods—less than 1%—compared to 7% for oral contraceptive pills. This reliability, combined with a low requirement for user adherence, has fueled rapid adoption, especially in developed countries with well-established healthcare systems.

Government programs are also promoting LARCs as part of comprehensive reproductive healthcare. For instance, the UK's National Health Service (NHS) includes hormonal IUDs in its publicly funded contraceptive offerings. In the U.S., state-level Medicaid expansion has been linked to increased access and uptake of LARCs, particularly in underserved populations. A report from the Kaiser Family Foundation found that the use of LARCs among U.S. women aged 15–44 increased from 8.5% in 2009 to 14% in 2020. In low- and middle-income countries, international bodies like UNFPA and USAID have rolled out LARC-focused initiatives to reduce unmet contraceptive needs. These global efforts, combined with innovations in hormonal implant technologies, are likely to sustain the rising demand for LARCs over the coming decade.

Digitalization and Telehealth Advancing Contraceptive Access

Digital health platforms and telemedicine are emerging as key enablers of hormonal contraceptive access, especially among younger, tech-savvy populations. The pandemic accelerated the shift to remote healthcare delivery, including virtual consultations for contraception. This trend is continuing in the post-pandemic era, with many healthcare systems integrating telehealth into their reproductive care offerings. Online platforms now allow patients to receive prescriptions for birth control pills, patches, and rings after a short digital consultation, which are then delivered directly to their homes. Companies in North America and Europe have launched subscription-based services tailored to individual health profiles. The U.S. Department of Health and Human Services (HHS) in 2022 reported that telehealth visits surged by over 60-fold from pre-pandemic levels, with reproductive health services being among the most requested.

Digital tools also offer enhanced privacy and convenience, critical for women in conservative societies or remote areas. In countries like India and Kenya, mobile apps are being used to educate women about contraceptive options and manage menstrual cycles, indirectly encouraging hormonal contraceptive adoption. Governments are also beginning to support this trend. For example, California’s Medicaid program allows telehealth-based contraceptive counseling and prescribing. The UK's NHS has piloted similar initiatives to reduce in-person clinic loads. As digital health infrastructure improves globally and mobile penetration increases, telehealth will become a critical driver in expanding access to hormonal contraceptives, ensuring both convenience and confidentiality.

Segmental Insights

Method Insights

Based on Method, Pills currently hold the largest share of the global market. Pills are the most widely used form of hormonal contraception due to their high efficacy, ease of use, wide availability, and cost-effectiveness. They are particularly preferred in both developed and developing regions because they can be self-administered and do not require clinical procedures, unlike intrauterine devices (IUDs) or implants. According to the World Health Organization (WHO), combined oral contraceptive pills are among the most common contraceptive methods used globally. In many countries, especially across North America and parts of Europe, over 20% of women of reproductive age report using the pill as their primary method of contraception. The pill is also gaining popularity in parts of Asia, Latin America, and Africa as healthcare infrastructure improves and awareness about family planning grows.

Download Free Sample Report

Regional Insights

Based on the region, North America accounted for the largest share of the global hormonal contraceptives market due to a combination of robust healthcare infrastructure, widespread awareness, proactive governmental initiatives, and high rates of contraceptive use. The region, particularly the United States and Canada, has implemented supportive reproductive health policies that promote access to a wide variety of contraceptive options, including pills, implants, injectables, and intrauterine devices (IUDs). The United States continues to lead the region, bolstered by federal programs such as Title X of the Public Health Service Act, which funds family planning services for low-income individuals. According to data from the Centers for Disease Control and Prevention (CDC), approximately 65% of women aged 15–49 in the U.S. were using some form of contraception as of the latest National Survey of Family Growth (NSFG). Hormonal methods, including the pill, patch, and vaginal ring, remain among the most widely used. Moreover, the Affordable Care Act (ACA) mandates that most insurance plans cover FDA-approved contraceptive methods without out-of-pocket costs, further increasing utilization and accessibility.

Recent Developments

• In March 2024, Perrigo Company plc announced the over the counter (OTC) availability of its oral contraceptive pill, Opill, in the United States. Consumers can now purchase the product without a prescription, including through the company's official website.
• In October 2023, Xiromed introduced EnilloRing, a generic version of the NuvaRing vaginal contraceptive ring, expanding contraceptive options for patients in the U.S. market.
• In March 2023, NEXT Life Sciences, Inc., a medical device company, launched Plan A, a new male contraceptive product. Designed to be safe, effective, and fully reversible, the product aims to provide a novel birth control solution specifically for men.
• In April 2023, Veru Inc. entered into a distribution agreement with Afaxys Group Services, LLC (AGS) for its FC2 Female Condom. Through this partnership, supported by AGS's Group Purchasing Organization (GPO), the product will be made more accessible to the over 31 million individuals who rely on public health clinics and community health centers for essential reproductive health services—benefiting both men and women.

Key Market Players

• Abbvie, Inc.
• Afaxys, Inc.
• Teva Pharmaceuticals Industries Ltd.
• Bayer AG
• Merck KGaA
• Organon Group of Companies
• Pfizer Inc.
• Johnson & Johnson Services, Inc.
• Lupin Pharmaceuticals, Inc.
• Pregna International Ltd.

Report Scope:

In this report, the Global Hormonal Contraceptives Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Hormonal Contraceptives Market, By Method:

o   Pill

o   Intrauterine Device

o   Injectable

o   Vaginal Ring

o   Implant

o   Others

• Hormonal Contraceptives Market, By Hormone:

o   Combination Hormonal Contraceptives

o   Progestin Only

• Hormonal Contraceptives Market, By Region:

o   North America

§  United States

§  Mexico

§  Canada

o   Europe

§  France

§  Germany

§  United Kingdom

§  Italy

§  Spain

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Japan

§  Australia

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East and Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Hormonal Contraceptives Market.

Available Customizations:

Global Hormonal Contraceptives Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Hormonal Contraceptives Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]